No Data Yet
ImmunityBio's conditional EMA approval for its cancer drug Anktiva is overshadowed by significant competition and financial risks, despite reporting $32.06M in revenue.
The European Medicines Agency's advisory committee has recommended conditional marketing authorization for ImmunityBio's ANKTIVA® (nogapendekin alfa inbakicept) combined with BCG. The positive opinion targets a high-risk form of bladder cancer, opening a significant new market for the company.